New shot cuts bleeding in hemophilia a patients
NCT ID NCT03315455
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tested emicizumab (Hemlibra) in 85 people with hemophilia A, a condition where blood doesn't clot properly, causing frequent bleeds. Participants received either emicizumab injections or no preventive treatment. The study found that those on emicizumab had significantly fewer bleeding episodes, suggesting it could be a valuable option for managing the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
emicizumab (Hemlibra)
What this could lead to
If successful, this could provide a more convenient and effective way to prevent bleeding episodes in people with hemophilia A, reducing the need for frequent intravenous treatments.
What could go wrong
The trial is completed and results are positive, but long-term safety and effectiveness in broader populations still need monitoring. Some patients may still experience breakthrough bleeds or side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Children's Hospital, Capital Medical University
Beijing, 100045, China
-
Peking Union Medical College Hospital
Beijing, 100730, China
-
Penang General Hospital
George Town, Pulau Pinang, 10990, Malaysia
-
Prince of Wales Hospital
Shatin, Hong Kong
-
Queen Elizabeth Hospital
Sabah, Sabah, 88586, Malaysia
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Ramathibodi Hospital
Bangkok, 10400, Thailand
-
Ruijin Hospital Shanghai Jiaotong University School of Medicine
Shanghai, 200025, China
-
Southern Medical University Nanfang Hospital
Guangdong Province Guangzhou City, 510515, China
-
Tianjin Institute of Hematology & Blood Diseases Hospital
Tianjin, 300020, China
-
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
Wuhan, 430030, China
-
Xiangya Hospital of Centre-South University
Changsha, 410008, China
-
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, 430022, China